STROMALab Médecine régénératrice, thérapie cellulaire, cellules souches mésenchymateuses, tissu adipeux, moelle osseuse, réparation, régénération Regenerative medicine, cell therapy, mesenchymal stem cells, adipose tissue, bone marrow, repair, regeneration

Team 1 : Plasticity of adipose tissue


Our team is one of the 2 teams of the STROMALab unit accredited by the university, Inserm, CNRS and EFS. Our common objective is the study and therapeutic use of stromal cells from 2 tissues: the bone marrow and adipose tissue. Bone marrow is seen here as a paradigm for understanding tissue homeostasis, its dysfunctions and how to restore it.
5 researchers and 6 teacher-researchers form the scientific backbone of our team, which explains the strong links with teaching. We are an integral part of the Toulouse Bio-Medical Research Federal Structure and have access to all Genotoul platforms.

We are one of the few teams in the world with strong expertise in the fields of adipose tissue, metabolism and regenerative medicine. Our studies focus on immature/stem cells from adipose tissue and their in vivo roles. We wish to define their physiological importance in the control of tissue homeostasis and its dysfunctions. Our team has always studied the plasticity of adipose tissue and focused on immature cells present in the stromal fraction as well as the importance of mitochondria and redox metabolism in the biology of these cells. We have thus demonstrated the angiogenic, cardiac and immunomodulatory properties of stem/stromal cells in adipose tissue. We have also demonstrated the beneficial effect of preconditioning targeting redox metabolism on some of these potentials. In parallel, we were the first to propose the existence of hematopoietic stem cells in adipose tissue and to demonstrate their role in physiopathology.

More recently, we have shown that stem/stromal cells from adipose tissue can migrate out of this tissue. All our results suggest that adipose tissue can be a physiological reservoir of immature cells that can be mobilized.

Several of these discoveries are patented. Thanks to the collaboration with EFS we have developed the production of these stem/stromal cells according to a GMP protocol which allows us to study their use in the framework of clinical cell therapy protocol.

Expected Health Outcomes :

From a cognitive point of view, our studies should allow us to better understand why and how the stroma is essential to the functioning of all tissues. From a therapeutic point of view, the expected benefits concern regenerative medicine and the development of innovative biotherapies that would use mesenchymal cells from bone marrow and adipose tissue.

5 researchers (CNRS, INSERM)

5 teachers-researchers (universitaire et hospitalier)

3 PhD student and 1 post-doctoral research associate

5 technical support